Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys 2007 Feb 01;67(2):480-4
Date
12/05/2006Pubmed ID
17141980DOI
10.1016/j.ijrobp.2006.09.004Scopus ID
2-s2.0-33846253557 (requires institutional sign-in at Scopus site) 33 CitationsAbstract
PURPOSE: To compare the outcomes for endometrial carcinoma patients treated with either high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy.
METHODS AND MATERIALS: This study included 1,179 patients divided into LDR (1,004) and HDR groups (175). Patients with International Federation of Gynecology and Obstetrics (FIGO) surgical Stages I-III were included. All patients were treated with postoperative irradiation. In the LDR group, the postoperative dose applied to the vaginal cuff was 60-70 Gy surface doses to the vaginal mucosa. The HDR brachytherapy prescription was 6 fractions of 2 Gy each to a depth of 0.5 cm from the surface of the vaginal mucosa. Overall survival, disease-free survival, local control, and complications were endpoints.
RESULTS: For all stages combined, the overall survival, disease-free survival, and local control at 5 years in the LDR group were 70%, 69%, and 81%, respectively. For all stages combined, the overall survival, disease-free survival, and local control at 5 years in the HDR group were 68%, 62%, and 78%, respectively. There were no significant differences in early or late Grade III and IV complications in the HDR or LDR groups.
CONCLUSION: Survival outcomes, pelvic tumor control, and Grade III and IV complications were not significantly different in the LDR brachytherapy group compared with the HDR group.
Author List
Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PWAuthor
Janet Sue Rader MD Chair, Professor in the Obstetrics and Gynecology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Aged, 80 and over
Brachytherapy
Child
Child, Preschool
Disease-Free Survival
Endometrial Neoplasms
Female
Humans
Infant
Middle Aged
Neoplasm Recurrence, Local
Radiotherapy Dosage
Regression Analysis
Treatment Outcome
